Direct covalent modification as a strategy to inhibit Nuclear Factor-Kappa B

Current Medicinal Chemistry

Volumn 16, Issue 32, 2009, Pages 4261-4273

  Pande, V ^a,b   Sousa, S F ^a   Ramos, M J ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Alkylating agents; Covalent modification; Cysteine; Nuclear Factor Kappa B; S nitrosylation; S thiolation

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ACETYLCYSTEINE; ACROLEIN; ANDROGRAPHOLIDE; ANTIOXIDANT; CROTONALDEHYDE; CRYPTOLEPINE; CYCLOPENTENONE; CYSTEINE; EPOXYQUINONE A MONOMER; GLUTATHIONE; HELENALIN; HERBIMYCIN A; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAMEBAKAURIN; KAURANE DERIVATIVE; N ACETYL S NITROSOPENICILLAMINE; NITROPRUSSIDE SODIUM; PARTHENOLIDE; PROSTAGLANDIN; PROSTAGLANDIN A1; PROTEIN P50; PROTEIN S; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; S NITROSOCYSTEINE; S NITROSOGLUTATHIONE; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONFORMATIONAL TRANSITION; COVALENT BOND; DNA BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVATION; HUMAN; INFLAMMATORY DISEASE; MOLECULAR RECOGNITION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION;

ALKYLATING AGENTS; CYSTEINE; NF-KAPPA B; NITROSATION; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SULFHYDRYL COMPOUNDS;

EID: 70450198853     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789578222     Document Type: Review

References (217)

1. Miyamoto, S.; Verma, I.M. Rel/Nf-Kappa-B/I-Kappa-B Story. Adv. Cancer Res., 1995, 66, 255-292.
2. Kopp, E.B.; Ghosh, S. Nf-Kappa-B and Rel Proteins in Innate Immunity. Adv. Immunol., 1995, 58, 1-27.
3. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial-cell adhesion molecules-Nf-kappa-B and cytokine-inducible enhancers. FASEB J., 1995, 9(10), 899-909.
4. Pierce, J.W.; Jamieson, C.A.; Ross, J.L.; Sen, R. Activation of Il-2 receptor alpha-chain gene by individual members of the rel oncogene family in association with serum response factor. J. Immunol., 1995, 155(4), 1972-1980.
5. Sperisen, P.; Wang, S.M.; Soldaini, E.; Pla, M.; Rusterholz, C.; Bucher, P.; Corthesy, P.; Reichenbach, P.; Nabholz, M. Mouse Interleukin-2 Receptor-Alpha Gene-Expression - Interleukin-1 and Interleukin-2 Control Transcription Via Distinct Cis-Acting Elements. J. Biol. Chem., 1995, 270(18), 10743-10753.
6. Tripathi, P.; Aggarwal, A. NF-kB transcription factor: a key player in the generation of immune response. Curr. Sci., 2006, 90(4), 519-531.
7. Gilmore, T.D. Introduction to NF-kappa B: players, pathways, perspectives. Oncogene, 2006, 25(51), 6680-6684.
8. Sen, R.; Baltimore, D. Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences. Cell, 1986, 46(5), 705-716. (Pubitemid 16020062)
9. Baeuerle, P.A.; Henkel, T. Function Amd Activation of Nf-Kappa- B in the Immune-System. Ann. Rev. Immunol., 1994, 12, 141-179.
10. Siebenlist, U.; Franzoso, G.; Brown, K. Structure, Regulation and Function of Nf-Kappa-B. Ann. Rev. Cell Biol., 1994, 10, 405-455.
11. Liou, H.C.; Baltimore, D. Regulation of the NF-kB/rel transcription factor and IkB inhibitor system. Curr. Opin. Cell Biol., 1993, 5(3), 477-487. (Pubitemid 223002976)
12. Grilli, M.; Chiu, J.J.S.; Lenardo, M.J. Nf-Kappa-B and Rel - Participants in a Multiform Transcriptional Regulatory System. Int. Rev. Cytol., 1993, 143, 1-62.
13. Israel, A. A Role for Phosphorylation and Degradation in the Control of Nf-Kappa-B Activity. Trends Genet., 1995, 11(6), 203-205.
14. Beg, A.A.; Baldwin, A.S. The I-kappa-B proteins - multifunctional regulators of rel/Nf-kappa-B transcription factors. Genes Dev., 1993, 7(11), 2064-2070. (Pubitemid 2010879)
15. Gilmore, T.D.; Morin, P.J. The IkB proteins: Members of a multifunctional family. Trends Genet., 1993, 9(12), 427-433. (Pubitemid 2016397)
16. Finco, T.S.; Baldwin, A.S. Mechanistic aspects of Nf-kappa-B regulation - the emerging role of phosphorylation and proteolysis. Immunity, 1995, 3(3), 263-272.
17. Verma, I.M.; Stevenson, J.K.; Schwarz, E.M.; Vanantwerp, D.; Miyamoto, S. Rel/Nf-Kappa-B/I-kappa-B family - intimate tales of association and dissociation. Genes Dev., 1995, 9(22), 2723-2735. (Pubitemid 3009952)
18. Wulczyn, F.G.; Krappmann, D.; Scheidereit, C. The NF-kB/Rel and IkB gene families: Mediators of immune response and inflammation. J. Mol. Med., 1996, 74(12), 749-769. (Pubitemid 26405603)
19. Lander, H.M.; Ogiste, J.S.; Pearce, S.F.A.; Levi, R.; Novogrodsky, A. Nitric oxide-stimulated guanine-nucleotide exchange on P21(Ras). J. Biol. Chem., 1995, 270(13), 7017-7020.
20. Scheinman, R.I.; Cogswell, P.C.; Lofquist, A.K.; Baldwin, A.S. Role of transcriptional activation of I-kappa-B-alpha in mediation of immunosuppression by glucocorticoids. Science, 1995, 270(5234), 283-286.
21. Frantz, B.; Nordby, E.C.; Bren, G.; Steffan, N.; Paya, C.V.; Kincaid, R.L.; Tocci, M.J.; Okeefe, S.J.; Oneill, E.A. Calcineurin acts in synergy with pma to inactivate I-kappa-B/Mad3, an inhibitor of Nf-kappa-B. EMBO J., 1994, 13(4), 861-870. (Pubitemid 24979440)
22. Davis, N.; Ghosh, S.; Simmons, D.L.; Tempst, P.; Liou, H.; Baltimore, D.; Bose, H.R. Rel-associated Pp40 - an inhibitor of the rel family of transcription factors. Science, 1991, 253(5025), 1268-1271.
23. Brown, K.; Gerstberger, S.; Carlson, L.; Franzoso, G.; Siebenlist, U. Central of I-kappa-B-alpha proteolysis by site-specific, signalinduced phosphorylation. Science, 1995, 267(5203), 1485-1488.
24. Rodriguez, M.S.; Michalopoulos, I.; Arenzanaseisdedos, F.; Hay, R.T. Inducible degradation of I-kappa-B-alpha in-vitro and in-vivo requires the acidic C-terminal domain of the protein. Mol. Cell. Biol., 1995, 15(5), 2413-2419.
25. Alkalay, I.; Yaron, A.; Hatzubai, A.; Orian, A.; Ciechanover, A.; Benneriah, Y. Stimulation-dependent I-kappa-B-alpha phosphorylation marks the Nf-kappa-B inhibitor for degradation via the ubiquitin- proteasome pathway. Proc. Natl. Acad. Sci. U.S.A., 1995, 92(23), 10599-10603.
26. Scherer, D.C.; Brockman, J.A.; Chen, Z.J.; Maniatis, T.; Ballard, D.W. Signal-induced degradation of I-kappa-B-alpha requires sitespecific ubiquitination. Proc. Natl. Acad. Sci. U.S.A., 1995, 92(24), 11259-11263.
27. Barroga, C.F.; Stevenson, J.K.; Schwarz, E.M.; Verma, I.M. Constitutive phosphorylation of I-kappa-B-alpha by casein kinase-Ii. Proc. Natl. Acad. Sci. U.S.A., 1995, 92(17), 7637-7641.
28. Elliott, P.J.; Ross, J.S. The proteasome - A new target for novel drug therapies. Am. J. Clin. Pathol., 2001, 116(5), 637-646. (Pubitemid 34453203)
29. Phelps, C.B.; Sengchanthalangsy, L.L.; Malek, S.; Ghosh, G. Mechanism of kappa B DNA binding by Rel/NF-kappa B dimers. J. Biol. Chem., 2000, 275(32), 24392-24399. (Pubitemid 30626529)
30. Berkowitz, B.; Huang, D.B.; Chen-Park, F.E.; Sigler, P.B.; Ghosh, G. The x-ray crystal structure of the NF-kappa B p50 center dot p65 heterodimer bound to the interferon beta-kappa B site. J. Biol. Chem., 2002, 277(27), 24694-24700. (Pubitemid 34952000)
31. Aradhya, S.; Nelson, D.L. NF-kappa B signaling and human disease. Curr. Opin. Genet. Dev., 2001, 11(3), 300-306.
32. Pande, V.; Ramos, M.J. NF-kappa B in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem., 2005, 12(3), 357-374.
33. Courtois, G.; Gilmore, T.D. Mutations in the NF-kappa B signaling pathway: implications for human disease. Oncogene, 2006, 25(51), 6831-6843. (Pubitemid 44657855)
34. Dolcet, X.; Llobet, D.; Pallares, J.; Matias-Guiu, X. NF-kB in development and progression of human cancer. Virchows Arch., 2005, 446(5), 475-482. (Pubitemid 40884279)
35. Shishodia, S.; Aggarwal, B.B. Nuclear factor-KB: a friend or a foe in cancer? Biochem. Pharmacol., 2004, 68(6), 1071-1080. (Pubitemid 39094272)
36. Luo, J.L.; Kamata, H.; Karin, M. IKK/NF-kappa B signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest., 2005, 115(10), 2625-2632. (Pubitemid 41434385)
37. Basseres, D.S.; Baldwin, A.S. Nuclear factor-kappa B and inhibitor of kappa B kinase pathways in oncogenic initiation and progression. Oncogene, 2006, 25(51), 6817-6830.
38. Pande, V.; Ramos, M.J. Nuclear Factor Kappa B: A potential target for anti-HIV chemotherapy. Curr. Med. Chem., 2003, 10(16), 1603-1615.
39. Sarkar, F.H.; Li, Y.W. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front. Biosci., 2008, 13, 2950-2959. (Pubitemid 351589211)
40. Collins, T.; Cybulsky, M.I. NF-kappa B: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 2001, 107(3), 255-264.
41. Valen, G.; Yan, Z.Q.; Hansson, G.K. Nuclear factor kappa-B and the heart. J. Am. Coll. Cardiol., 2001, 38(2), 307-314.
42. Pahl, A.; Szelenyi, I. Asthma therapy in the new millennium. Inflammat. Res., 2002, 51(6), 273-282.
43. Roshak, A.K.; Callahan, J.F.; Blake, S.M. Small-molecule inhibitors of NF-kappa B for the treatment of inflammatory joint disease. Curr. Opin. Pharmacol., 2002, 2(3), 316-321. (Pubitemid 34594375)
44. Reuter, U.; Chiarugi, A.; Bolay, H.; Moskowitz, M.A. Nuclear factor-kappa B as a molecular target for migraine therapy. Ann. Neurol., 2002, 51(4), 507-516. (Pubitemid 34260781)
45. Holmes-McNary, M. Nuclear factor kappa B signaling in catabolic disorders. Curr. Opin. Clin. Nutrit. Metabol. Care, 2002, 5(3), 255-263. (Pubitemid 40684670)
46. Ho, E.; Bray, T.M. In Experimental Biology Meeting: Washington, D.C. 1999, pp. 205-213.
47. Yuan, M.S.; Konstantopoulos, N.; Lee, J.S.; Hansen, L.; Li, Z.W.; Karin, M.; Shoelson, S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK beta. Science, 2001, 293(5535), 1673-1677.
48. Chung, H.Y.; Kim, H.J.; Kim, K.W.; Choi, J.S.; Yu, B.P. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microscop. Res. Technique, 2002, 59(4), 264-272.
49. Bell, S.; Degitz, K.; Quirling, M.; Jilg, N.; Page, S.; Brand, K. Involvement of NF-kappa B signalling in skin physiology and disease. Cell Signal., 2003, 15(1), 1-7. (Pubitemid 35223623)
50. Guijarro, C.; Egido, J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Intern., 2001, 59(2), 415-424. (Pubitemid 32157906)
51. Neurath, M.F.; Becker, C.; Barbulescu, K. Role of NF-kappa B in immune and inflammatory responses in the gut. Gut, 1998, 43(6), 856-860. (Pubitemid 28539668)
52. Dijkstra, G.; Moshage, H.; Jansen, P.L.M. Blockade of NF-kappa B activation and donation of nitric oxide: New treatment options in inflammatory bowel disease? Scandinavian J. Gastroenterol., 2002, 37, 37-41.
53. Weber, C.K.; Adler, G. In 2nd Meeting of Mediterranean- Societies-of-Pancreatology: Santorini, Greece, 2001, pp. 356-362.
54. Mattson, M.P.; Camandola, S. NF-kappa B in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest., 2001, 107(3), 247-254. (Pubitemid 32162153)
55. Christman, J.W.; Sadikot, R.T.; Blackwell, T.S. The role of nuclear factor-kappa B in pulmonary diseases. Chest, 2000, 117(5), 1482-1487.
56. Barnes, P.J. New treatments for COPD. Nat. Rev. Drug Discov., 2002, 1(6), 437-446.
57. Wratten, M.L.; Brendolan, A.; Ronco, C.; La Greca, G.; Tetta, C. In 2nd International Course on Critical Care Nephrology. Ronco, C.; Bellomo, R.; LaGreca, G. Eds.: Vicenza, Italy, 2001, pp 400-414.
58. Lavie, L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med. Rev., 2003, 7(1), 35-51. (Pubitemid 36188305)
59. Christman, J.W.; Blackwell, T.S.; Juurlink, B.H.J. Redox regulation of nuclear factor kappa B: Therapeutic potential for attenuating inflammatory responses. Brain Pathol., 2000, 10(1), 153-162.
60. Na, H.K.; Surh, Y.J. Transcriptional regulation via cysteine thiol modification: A novel molecular strategy for chemoprevention and cytoprotection. Mol. Carcinog., 2006, 45(6), 368-380.
61. Karin, M.; Yamamoto, Y.; Wang, Q.M. The IKKNF-kappa B system: A treasure trove for drug development. Nat. Rev. Drug Discov., 2004, 3(1), 17-26. (Pubitemid 38088695)
62. Wietek, C.; O'Neill, L.A.J. Diversity and regulation in the NFkappa B system. Trends Biochem. Sci., 2007, 32(7), 311-319.
63. Gilmore, T.D.; Herscovitch, M. Inhibitors of NF-kappa B signaling: 785 and counting. Oncogene, 2006, 25(51), 6887-6899. (Pubitemid 44657858)
64. Sharma, R.K.; Otsuka, M.; Pande, V.; Inoue, J.; Ramos, M.J. Evans Blue is an inhibitor of nuclear factor-kappa B (NF-kappa B)-DNA binding. Bioorg. Med. Chem. Lett., 2004, 14(24), 6123-6127.
65. Pande, V.; Sharma, R.K.; Inoue, J.I.; Otsuka, M.; Ramos, M.J. A molecular modeling study of inhibitors of nuclear factor kappa-B (p50) - DNA binding. J. Comput. Aided Mol. Des., 2003, 17(12), 825-836.
66. Flohe, L.; BrigeliusFlohe, R.; Saliou, C.; Traber, M.G.; Packer, L. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med., 1997, 22(6), 1115-1126.
67. Schreck, R.; Albermann, K.; Baeuerle, P.A. Nuclear factor kappa-B - an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun., 1992, 17(4), 221-237.
68. Schmidt, K.N.; Amstad, P.; Cerutti, P.; Baeuerle, P.A. Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-kb. Adv. Exp. Med. Biol., 1996, 387, 63-68.
69. Iuvone, T.; D'Acquisto, F.; Van Osselaer, N.; Di Rosa, M.; Carnuccio, R.; Herman, A.G. Evidence that inducible nitric oxide synthase is involved in LPS-induced plasma leakage in rat skin through the activation of nuclear factor-kappa B. Br. J. Pharmacol., 1998, 123(7), 1325-1330.
70. Staal, F.J.T.; Roederer, M.; Herzenberg, L.A.; Herzenberg, L.A. Intracellular thiols regulate activation of nuclear factor kappa-B and transcription of human-immunodeficiency-virus. Proc. Natl. Acad. Sci. U.S.A., 1990, 87(24), 9943-9947.
71. KretzRemy, C.; Mehlen, P.; Mirault, M.E.; Arrigo, A.P. Inhibition of I kappa B-alpha phosphorylation and degradation and subsequent NF-kappa B activation by glutathione peroxidase overexpression. J. Cell Biol., 1996, 133(5), 1083-1093. (Pubitemid 26172513)
72. Manna, S.K.; Kuo, M.T.; Aggarwal, B.B. Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factorkappa B and activator protein-1. Oncogene, 1999, 18(30), 4371-4382.
73. Gius, D.; Botero, A.; Shah, S.; Curry, H.A. Intracellular oxidation reduction status in the regulation of transcription factors NF-kappa B and AP-1. Toxicol. Lett., 1999, 106(2-3), 93-106.
74. Dalton, T.D.; Shertzer, H.G.; Puga, A. Regulation of gene expression by reactive oxygen. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 67-101. (Pubitemid 29222552)
75. Bubici, C.; Papa, S.; Dean, K.; Franzoso, G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene, 2006, 25(51), 6731-6748. (Pubitemid 44657849)
76. Dickinson, L.A.; Trauger, J.W.; Baird, E.E.; Dervan, P.B.; Graves, B.J.; Gottesfeld, J.M. Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappa B, and DNA by a designed DNA-binding ligand. J. Biol. Chem., 1999, 274(18), 12765-12773. (Pubitemid 129518049)
77. Nishi, T.; Shimizu, N.; Hiramoto, M.; Sato, L.; Yamaguchi, Y.; Hasegawa, M.; Aizawa, S.; Tanaka, H.; Kataoka, K.; Watanabe, H.; Handa, H. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem., 2002, 277(46), 44548-44556. (Pubitemid 36157890)
78. Kurland, J.F.; Kodym, R.; Story, M.D.; Spurgers, K.B.; McDonnell, T.J.; Meyn, R.E. NF-kappa B1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J. Biol. Chem., 2001, 276(48), 45380-45386.
79. Kumar, S.; Rabson, A.B.; Gelinas, C. The Rxxrxrxxc motif conserved in all rel kappa-B proteins is essential for the DNA-binding activity and redox regulation of the V-rel oncoprotein. Mol. Cell. Biol., 1992, 12(7), 3094-3106.
80. Matthews, J.R.; Kaszubska, W.; Turcatti, G.; Wells, T.N.C.; Hay, R.T. Role of cysteine62 in DNA recognition by the P50 subunit of Nf-kappa-B. Nucleic Acids Res., 1993, 21(8), 1727-1734. (Pubitemid 23178885)
81. Matthews, J.R.; Wakasugi, N.; Virelizier, J.L.; Yodoi, J.; Hay, R.T. Thioredoxin regulates the DNA-binding activity of Nf-Chi-B by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res., 1992, 20(15), 3821-3830.
82. Tjalkens, R.B.; Luckey, S.W.; Kroll, D.J.; Petersen, D.R. alpha, beta-unsaturated aldehydes increase glutathione S-transferase mRNA and protein: Correlation with activation of the antioxidant response element. Arch. Biochem. Biophys., 1998, 359(1), 42-50.
83. Pineda-Molina, E.; Klatt, P.; Vazquez, J.; Marina, A.; de Lacoba, M.G.; Perez-Sala, D.; Lamas, S. Glutathionylation of the p50 subunit of NF-kappa B: a mechanism for redox-induced inhibition of DNA binding. Biochemistry, 2001, 40(47), 14134-14142. (Pubitemid 33081616)
84. Abate, C.; Patel, L.; Rauscher, F.J.; Curran, T. Redox regulation of fos and jun dna-binding activity in vitro. Science, 1990, 249(4973), 1157-1161. (Pubitemid 20337316)
85. Klatt, P.; Molina, E.P.; Lamas, S. Nitric oxide inhibits c-Jun DNA binding by specifically targeted S-glutathionylation. J. Biol. Chem., 1999, 274(22), 15857-15864. (Pubitemid 129518948)
86. Zheng, M.; Aslund, F.; Storz, G. Activation of the OxyR transcription factor by reversible disulfide bond formation. Science, 1998, 279(5357), 1718-1721. (Pubitemid 28164467)
87. Mohr, S.; Zech, B.; Lapetina, E.G.; Brune, B. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem. Biophys. Res. Commun., 1997, 238(2), 387-391. (Pubitemid 27464394)
88. Yun, H.Y.; Gonzalez-Zulueta, M.; Dawson, V.L.; Dawson, T.M. Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21(ras). Proc. Natl. Acad. Sci. U.S.A., 1998, 95(10), 5773-5778. (Pubitemid 28224172)
89. Soberman, R.J. The expanding network of redox signaling: new observations, complexities, and perspectives. J. Clin. Invest., 2003, 111(5), 571-574.
90. Marnett, L.J.; Riggins, J.N.; West, J.D. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J. Clin. Invest., 2003, 111(5), 583-593.
91. Gilbert, H.F. Molecular and cellular aspects of thiol disulfide exchange. Adv. Enzymol. Relat. Areas Mol. Biol., 1990, 63, 69-172.
92. Chen, F.E.; Huang, D.B.; Chen, Y.Q.; Ghosh, G. Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA. Nature, 1998, 391(6665), 410-413. (Pubitemid 28093519)
93. Ghosh, G.; Vanduyne, G.; Ghosh, S.; Sigler, P.B. Structure of Nf- Kappa-B P50 Homodimer Bound to a Kappa-B Site. Nature, 1995, 373(6512), 303-310.
94. Muller, C.W.; Rey, F.A.; Sodeoka, M.; Verdine, G.L.; Harrison, S.C. Structure of the Nf-kappa-B P50 homodimer bound to DNA. Nature, 1995, 373(6512), 311-317.
95. Chai, Y.C.; Hendrich, S.; Thomas, J.A. Protein S-thiolation in hepatocytes stimulated by T-butyl hydroperoxide, menadione, and neutrophils. Arch. Biochem. Biophys., 1994, 310(1), 264-272.
96. Chai, Y.C.; Ashraf, S.S.; Rokutan, K.; Johnston, R.B.; Thomas, J.A. S-thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst - evidence against a role for glutathione disulfide. Arch. Biochem. Biophys., 1994, 310(1), 273-281.
97. Ravichandran, V.; Seres, T.; Moriguchi, T.; Thomas, J.A.; Johnston, R.B. S-thiolation of glyceraldehyde-3-phosphate dehydrogenase induced by the phagocytosis-associated respiratory burst in blood monocytes. J. Biol. Chem., 1994, 269(40), 25010-25015. (Pubitemid 24311768)
98. Claiborne, A.; Yeh, J.I.; Mallett, T.C.; Luba, J.; Crane, E.J.; Charrier, V.; Parsonage, D. Protein-sulfenic acids: Diverse roles for an unlikely player in enzyme catalysis and redox regulation. Biochemistry, 1999, 38(47), 15407-15416.
99. Park, E.M.; Thomas, J.A. S-thiolation of creatine-kinase and glycogen phosphorylase-b initiated by partially reduced oxygen species. Biochim. Biophys. Acta, 1988, 964(2), 151-160.
100. Miller, R.M.; Sies, H.; Park, E.M.; Thomas, J.A. Phosphorylase and creatine-kinase modification by thiol disulfide exchange and by xanthine oxidase-initiated S-thiolation. Arch. Biochem. Biophys., 1990, 276(2), 355-363.
101. Jung, C.H.; Thomas, J.A. S-glutathiolated hepatocyte proteins and insulin disulfides as substrates for reduction by glutaredoxin, thioredoxin, protein disulfide isomerase, and glutathione. Arch. Biochem. Biophys., 1996, 335(1), 61-72.
102. Viner, R.I.; Williams, T.D.; Schoneich, C. Peroxynitrite modification of protein thiols: Oxidation, nitrosylation, and S-glutathiolation of functionally important cysteine residue(s) in the sarcoplasmic reticulum Ca-ATPase. Biochemistry, 1999, 38(38), 12408-12415. (Pubitemid 129516210)
103. Kalayjian, R.C.; Skowron, G.; Emgushov, R.T.; Chance, M.; Spell, S.A.; Borum, P.R.; Webb, L.S.; Mayer, K.H.; Jackson, J.B.; Yenlieberman, B.; Story, K.O.; Rowe, W.B.; Thompson, K.; Goldberg, D.; Trimbo, S.; Lederman, M.M. A phase I/Ii trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asympto matic hiv-infected subjects. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1994, 7(4), 369-374.
104. Wodak, S.J.; Decoen, J.L.; Edelstein, S.J.; Demarne, H.; Beuzard, Y. Modification of human-hemoglobin by glutathione .3. perturbations of hemoglobin conformation analyzed by computer modeling. J. Biol. Chem., 1986, 261(31), 4717-4724.
105. Hagen, T.M.; Wierzbicka, G.T.; Sillau, A.H.; Bowman, B.B.; Jones, D.P. Bioavailability of dietary glutathione - effect on plasma-concentration. Am. J. Physiol., 1990, 259(4), G524-G529. (Pubitemid 20340458)
106. Simon, G.; Moog, C.; Obert, G. Effects of glutathione precursors on human-immunodeficiency-virus replication. Chem. Biol. Interact., 1994, 91(2-3), 217-224. (Pubitemid 24168468)
107. Droge, W. Cysteine and glutathione deficiency in aids patients - a rationale for the treatment with N-acetyl-cysteine. Pharmacology, 1993, 46(2), 61-65.
108. Hoffer, E.; Baum, Y.; Tabak, A.; Taitelman, U. N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Toxicol. Lett., 1996, 84(1), 7-12. (Pubitemid 26052946)
109. Bernard, G.R.; Wheeler, A.P.; Arons, M.M.; Morris, P.E.; Paz, H.L.; Russell, J.A.; Wright, P.E.; Bernard, G.R.; Arons, M.M.; Wheeler, A.P.; Carmichael, L.C.; Morris, P.E.; Higgins, S.B.; Dupont, W.D.; Edens, T.R.; Swindell, B.B.; Russell, J.A.; Paz, H.L.; Wright, P.E.; Steinberg, K.P. A trial of antioxidants Nacetylcysteine and procysteine in ARDS. Chest, 1997, 112(1), 164-172.
110. Ghezzi, P.; Di Sirnplicio, P. Glutathionylation pathways in drug response. Curr. Opin. Pharmacol., 2007, 7(4), 398-403.
111. Powis, G.; Kirkpatrick, D.L. Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol., 2007, 7(4), 392-397. (Pubitemid 47289261)
112. Tanaka, T.; Nakamura, H.; Nishiyama, A.; Hosoi, F.; Masutani, H.; Wada, H.; Yodoi, J. In International Symposium on Free Radicals in Life Science; Harwood Acad Publ Gmbh: Tokyo, Japan, 2000, pp 851-855.
113. Mohr, S.; Hallak, H.; de Boitte, A.; Lapetina, E.G.; Brune, B. Nitric oxide induced S-glutathionylation and inactivation of glyceraldehyde- 3-phosphate dehydrogenase. J. Biol. Chem., 1999, 274(14), 9427-9430. (Pubitemid 129517913)
114. Konorev, E.A.; Kalyanaraman, B.; Hogg, N. Modification of creatine kinase by S-nitrosothiols: S-nitrosation vs. S-thiolation. Free Radic. Biol. Med., 2000, 28(11), 1671-1678. (Pubitemid 30628471)
115. Mallis, R.J.; Thomas, J.A. Effect of S-nitrosothiols on cellular glutathione and reactive protein sulfhydryls. Arch. Biochem. Biophys., 2000, 383(1), 60-69.
116. Hess, D.T.; Matsumoto, A.; Nudelman, R.; Stamler, J.S. Snitrosylation: spectrum and specificity. Nat. Cell Biol., 2001, 3(2), E46-E49.
117. Hogg, N. The biochemistry and physiology of S-nitrosothiols. Annu. Rev. Pharmacol. Toxicol., 2002, 42, 585-600.
118. Jaffrey, S.R.; Erdjument-Bromage, H.; Ferris, C.D.; Tempst, P.; Snyder, S.H. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat. Cell Biol., 2001, 3(2), 193-197.
119. Gow, A.J.; Chen, Q.P.; Hess, D.T.; Day, B.J.; Ischiropoulos, H.; Stamler, J.S. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J. Biol. Chem., 2002, 277(12), 9637-9640.
120. Matthews, J.R.; Hay, R.T. Regulation of the DNA-binding activity of Nf-kappa-B. Int. J. Biochem. Cell Biol., 1995, 27(9), 865-879.
121. Matthews, J.R.; Botting, C.H.; Panico, M.; Morris, H.R.; Hay, R.T. Inhibition of NF-kappa B DNA binding by nitric oxide. Nucleic Acids Res., 1996, 24(12), 2236-2242. (Pubitemid 26193585)
122. Marshall, H.E.; Stamler, J.S. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry, 2001, 40(6), 1688-1693.
123. Moncada, S.; Higgs, A.; Furchgott, R. XIV. International union of pharmacology nomenclature in nitric oxide research. Pharmacol. Rev., 1997, 49(2), 137-142.
124. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43(2), 109-142.
125. Peng, H.B.; Libby, P.; Liao, J.K. Induction and stabilization of IkBa by nitric oxide mediates inhibition of NF-kB. J. Biol. Chem., 1995, 270(23), 14214-14219.
126. Sayre, L.M.; Smith, M.A.; Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem., 2001, 8(7), 721-738. (Pubitemid 32427903)
127. Uchida, K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med., 2000, 28(12), 1685-1696. (Pubitemid 30628655)
128. Stevens, J.F.; Maier, C.S. Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol. Nutr. Food Res., 2008, 52(1), 7-25.
129. Lambert, C.; Li, J.; Jonscher, K.; Yang, T.C.; Reigan, P.; Quintana, M.; Harvey, J.; Freed, B.M. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappa B1 DNA binding domain. J. Biol. Chem., 2007, 282(27), 19666-19675.
130. Straus, D.S.; Glass, C.K. Cyclopentenone prostaglandins: New insights on biological activities and cellular targets. Med. Res. Rev., 2001, 21(3), 185-210.
131. Powell, W.S. 15-deoxy-Delta(12,14-)PGJ(2): endogenous PPAR gamma ligand or minor eicosanoid degradation product? J. Clin. Invest., 2003, 112(6), 828-830.
132. Soberman, R.J.; Christmas, P. The organization and consequences of eicosanoid signaling. J. Clin. Invest., 2003, 111(8), 1107-1113.
133. Clay, C.E.; Namen, A.M.; Atsumi, G.; Willingham, M.C.; High, K.P.; Kute, T.E.; Trimboli, A.J.; Fonteh, A.N.; Dawson, P.A.; Chilton, F.H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis, 1999, 20(10), 1905-1911. (Pubitemid 29476115)
134. Li, L.; Tao, J.; Davaille, J.; Fe?ral, C.; Mallat, A.; Rieusset, J.; Vidal, H.; Lotersztajn, S. 15-Deoxy-delta-12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferatoractivated receptors. J. Biol. Chem., 2001, 276(41), 38152-38158. (Pubitemid 37384069)
135. Ianaro, A.; Ialenti, A.; Maffia, P.; Di Meglio, P.; Di Rosa, M.; Santoro, M.G. Anti-inflammatory activity of 15-deoxy-Delta (12,14)-PGJ(2) and 2-cyclopenten-1-one: Role of the heat shock response. Mol. Pharmacol., 2003, 64(1), 85-93.
136. Fahmi, H.; Pelletier, J.P.; Mineau, F.; Martel-Pelletier, J. 15d-PGJ2 is acting as a 'dual agent' on the regulation of COX-2 expression in human osteoarthritic chondrocytes. Osteoarthr. Cartil., 2002, 10(11), 845-848.
137. Cuzzocrea, S.; Wayman, N.S.; Mazzon, E.; Dugo, L.; Di Paola, R.; Serraino, I.; Britti, D.; Chatterjee, P.K.; Caputi, A.P.; Thiemermann, C. The cyclopentenone prostaglandin 15-deoxy-Delta (12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation. Mol. Pharmacol., 2002, 61(5), 997-1007. (Pubitemid 34441764)
138. Winnett, G.; Van Hagen, D.; Schrey, M. Prostaglandin J2 metabolites inhibit aromatase activity by redox-sensitive mechanisms: Potential implications for breast cancer therapy. Int. J. Cancer, 2003, 103(5), 600-605. (Pubitemid 36091462)
139. Kondo, M.; Shibata, T.; Kumagai, T.; Osawa, T.; Shibata, N.; Kobayashi, M.; Sasaki, S.; Iwata, M.; Noguchi, N.; Uchida, K. 15- deoxy-Delta(12,14)- prostaglandin J(2): The endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(11), 7367-7372. (Pubitemid 34568697)
140. Monneret, G.; Li, H.; Vasilescu, J.; Rokach, J.; Powell, W.S. 15-Deoxy-Delta12,14-prostaglandins D2 and J2 are potent activators of human eosinophils. J. Immunol., 2002, 168(7), 3563-3569.
141. Kawamoto, Y.; Nakamura, Y.; Naito, Y.; Torii, Y.; Kumagai, T.; Osawa, T.; Ohigashi, H.; Satoh, K.; Imagawa, M.; Uchida, K. Cyclopentenone prostaglandins as potential inducers of phase II detoxification enzymes - 15-deoxy-Delta(12,14) -prostaglandin J2-induced expression of glutathione S-transferases. J. Biol. Chem., 2000, 275(15), 11291-11299. (Pubitemid 30212777)
142. Vosseler, C.A.; Erl, W.; Weber, P.C. Structural requirements of cyclopentenone prostaglandins to induce endothelial cell apoptosis. Biochem. Biophys. Res. Commun., 2003, 307(2), 322-326.
143. Fitzpatrick, F.A.; Wynalda, M.A. Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro. J. Biol. Chem., 1983, 258(19), 11713-11718.
144. Forman, B.M.; Tontonoz, P.; Chen, J.; Brun, R.P.; Spiegelman, B.M.; Evans, R.M. 15-Deoxy-Delta(12,14)-Prostaglandin J(2) Is a Ligand for the Adipocyte Determination Factor Ppar-Gamma. Cell, 1995, 83(5), 803-812.
145. Kliewer, S.A.; Lenhard, J.M.; Willson, T.M.; Patel, I.; Morris, D.C.; Lehmann, J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 1995, 83(5), 813-819.
146. Schoonjans, K.; Martin, G.; Staels, B.; Auwerx, J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol., 1997, 8(3), 159-166. (Pubitemid 27290462)
147. Fajas, L.; Fruchart, J.C.; Auwerx, J. Transcriptional control of adipogenesis. Curr. Opin. Cell Biol., 1998, 10(2), 165-173.
148. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688. (Pubitemid 30650602)
149. Straus, D.S.; Pascual, G.; Li, M.; Welch, J.S.; Ricote, M.; Hsiang, C.H.; Sengchanthalangsy, L.L.; Ghosh, G.; Glass, C.K. 15-deoxy-Delta(12,14)- prostaglandin J(2) inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U.S.A., 2000, 97(9), 4844-4849.
150. Rossi, A.; Kapahi, P.; Natoli, G.; Takahashi, T.; Chen, Y.; Karin, M.; Santoro, M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase. Nature, 2000, 403(6765), 103-108.
151. Perez-Sala, D.; Cernuda-Morollon, E.; Pineda-Molina, E.; Canada, F.J. Contribution of covalent protein modification to the antiinflammatory effects of cyclopentenone prostaglandins. Ann. N. Y. Acad. Sci., 2002, 973, 533-536.
152. Cernuda-Morollon, E.; Pineda-Molina, E.; Javier Canada, F.; Perez-sala, D. 15-deoxy-delta12,14-prostaglandin J2 inhibition of NF-kB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem., 2001, 276(38), 35530-35536.
153. Akimaru, K.; Kuo, M.T.; Furuta, K.; Suzuki, M.; Noyori, R.; Ishikawa, T. Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins. Cytotechnology, 1996, 19(3), 221-227. (Pubitemid 26324496)
154. Evers, R.; Cnubben, N.H.P.; Wijnholds, J.; van Deemter, L.; van Bladeren, P.J.; Borst, P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett., 1997, 419(1), 112-116. (Pubitemid 28011228)
155. Ishikawa, T.; Akimaru, K.; Nakanishi, M.; Tomokiyo, K.; Furuta, K.; Suzuki, M.; Noyori, R. Anti-cancer-prostaglandin-induced cell-cycle arrest and its modulation by an inhibitor of the ATPdependent glutathione S-conjugate export pump (GS-X pump). Biochem. J., 1998, 336(3), 569-576. (Pubitemid 29008014)
156. Suzuki, M.; Mori, M.; Niwa, T.; Hirata, R.; Furuta, K.; Ishikawa, T.; Noyori, R. Chemical implications for antitumor and antiviral prostaglandins: Reaction of Delta7-prostaglandin A1 and prostaglandin A1 methyl esters with thiols. J. Am. Chem. Soc., 1997, 119(10), 2376-2385. (Pubitemid 27167854)
157. Satoh, T.; Furuta, K.; Tomokiyo, K.; Namura, S.; Nakatsuka, D.; Sugie, Y.; Ishikawa, Y.; Hatanaka, H.; Suzuki, M.; Watanabe, Y. Neurotrophic actions of novel compounds designed from cyclopentenone prostaglandins. J. Neurochem., 2001, 77(1), 50-62. (Pubitemid 32245079)
158. Fukushima, M. Prostaglandin-J2 - antitumor and antiviral activities and the mechanisms involved. Eicosanoids, 1990, 3(4), 189-199.
159. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I.P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J.C.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARalfa but not by PPARgamma activators. Nature, 1998, 393(6687), 790-793. (Pubitemid 28299490)
160. Jiang, C.Y.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998, 391(6662), 82-86. (Pubitemid 28079219)
161. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391(6662), 79-82.
162. Li, M.; Pascual, G.; Glass, C.K. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell Biol., 2000, 20(13), 4699-4707. (Pubitemid 30396117)
163. Bureau, F.; Desmet, C.; Melotte, D.; Jaspar, F.; Volanti, C.; Vanderplasschen, A.; Pastoret, P.P.; Piette, J.; Lekeux, P. A proinflammatory role for the cyclopentenone prostaglandins at low micromolar concentrations: Oxidative stress-induced extracellular signal-regulated kinase activation without NF-?B inhibition. J. Immunol., 2002, 168(10), 5318-5325. (Pubitemid 34496000)
164. Perez-Sala, D.; Cernuda-Morollon, E.; Canada, F.J. Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta(12,14)-prostaglandin J(2). J. Biol. Chem., 2003, 278(51), 51251-51260. (Pubitemid 38020362)
165. Shibata, T.; Yamada, T.; Kondo, M.; Tanahashi, N.; Tanaka, K.; Nakamura, H.; Masutani, H.; Yodoi, J.; Uchida, K. An endogenous electrophile that modulates the regulatory mechanism of protein turnover: Inhibitory effects of 15-deoxy-gamma 12,14- prostaglandin J2 on proteasome. Biochemistry, 2003, 42(47), 13960-13968. (Pubitemid 37466621)
166. Shibata, T.; Yamada, T.; Ishii, T.; Kumazawa, S.; Nakamura, H.; Masutani, H.; Yodoi, J.; Uchida, K. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J. Biol. Chem., 2003, 278(28), 26046-26054. (Pubitemid 36835372)
167. Suzuki, M.; Kiho, T.; Tomokiyo, K.; Furuta, K.; Fukushima, S.; Takeuchi, Y.; Nakanishi, M.; Noyori, R. Rational design of antitumor prostaglandins with high biological stability. J. Med. Chem., 1998, 41(16), 3084-3090. (Pubitemid 28359944)
168. Seaman, F.C. Sesquiterpene lactones as taxonomic characters in the asteraceae. Bot. Rev., 1982, 48(2), 121-595.
169. Lee, K.H.; Hall, I.H.; Mar, E.C. Sesquiterpene antitumor agents: inhibitors of cellular metabolism. Science, 1977, 196(4289), 533-536.
170. Hall, I.H.; Lee, K.H.; Starnes, C.O. Anti-inflammatory activity of sesquiterpene lactones and related compounds. J. Pharm. Sci., 1979, 68(5), 537-542. (Pubitemid 9186368)
171. Schmidt, T.J. Helenanolide-type sesquiterpene lactones .3. Rates and stereochemistry in the reaction of helenalin and related helenanolides with sulfhydryl containing biomolecules. Bioorg. Med. Chem., 1997, 5(4), 645-653.
172. Lyss, G.; Schmidt, T.J.; Merfort, I.; Pahl, H.L. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappa B. Biol. Chem., 1997, 378(9), 951-961.
173. Lyss, G.; Knorre, A.; Schmidt, T.J.; Pahl, H.L.; Merfort, I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappa B by directly targeting p65. J. Biol. Chem., 1998, 273(50), 33508-33516. (Pubitemid 29005734)
174. Rungeler, P.; Lyss, G.; Castro, V.; Mora, G.; Pahl, H.L.; Merfort, I. Study of three sesquiterpene lactones from Tithonia diversifolia on their anti-inflammatory activity using the transcription factor NF-kappa B and enzymes of the arachidonic acid pathway as targets. Planta Med., 1998, 64(7), 588-593. (Pubitemid 28481467)
175. Kupchan, S.M.; Fessler, D.C.; Eakin, M.A.; Giacobbe, T.J. Reactions of alpha methylene lactone tumor inhibitors with model biological nucleophiles. Science, 1970, 168(3929), 376-378.
176. Garcia-Pineres, A.J.; Castro, V.; Mora, G.; Schmidt, T.J.; Strunck, E.; Pahl, H.L.; Merfort, I. Cysteine 38 in p65/NF-kappa B plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem., 2001, 276(43), 39713-39720. (Pubitemid 37391376)
177. Rungeler, P.; Castro, V.; Mora, G.; Goren, N.; Vichnewski, W.; Pahl, H.L.; Merfort, I.; Schmidt, T.J. Inhibition of transcription factor NF-kappa B by sesquiterpene lactones: a proposed molecular mechanism of action. Bioorg. Med. Chem., 1999, 7(11), 2343-2352.
178. Hehner, S.P.; Heinrich, M.; Bork, P.M.; Vogt, M.; Ratter, F.; Lehmann, V.; Schulze-Osthoff, K.; Droge, W.; Schmitz, M.L. Sesquiterpene lactones specifically inhibit activation of NF-kB by preventing the degradation of IkB-alfa and IkB-beta. J. Biol. Chem., 1998, 273(3), 1288-1297.
179. Hehner, S.P.; Hofmann, T.G.; Droge, W.; Schmitz, M.L. The anti-inflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J. Immunol., 1999, 163(10), 5617-5623.
180. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking: Current status and future challenges. Proteins, 2006, 65(1), 15-26. (Pubitemid 44320611)
181. Taylor, R.D.; Jewsbury, P.J.; Essex, J.W. A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des., 2002, 16(3), 151-166.
182. Leach, A.R.; Shoichet, B.K.; Peishoff, C.E. Prediction of proteinligand interactions. Docking and scoring: Successes and gaps. J. Med. Chem., 2006, 49(20), 5851-5855.
183. Fujita, T.; Takeda, Y.; Sun, H.D.; Minami, Y.; Marunaka, T.; Takeda, S.; Yamada, Y.; Togo, T. Cyto-toxic and antitumor activities of rabdosia diterpenoids. Planta Med., 1988(5), 414-417.
184. Bang Yeon, H.; Lee, J.H.; Tae Hyeon, K.; Hang Sub, K.; Young Soo, H.; Jai Seup, R.; Kyong Soon, L.; Jung Joon, L. Kaurane diterpenes from Isodon japonicus inhibit nitric oxide and prostaglandin E2 production and NF-kB activation in LPS-stimulated macrophage RAW264.7 cells. Planta Med., 2001, 67(5), 406-410. (Pubitemid 32652574)
185. Lee, J.H.; Koo, T.H.; Hwang, B.Y.; Lee, J.J. Kaurane diterpene, kamebakaurin, inhibits NF-kB by directly targeting the DNAbinding activity of p50 and blocks the expression of antiapoptotic NF-kB target genes. J. Biol. Chem., 2002, 277(21), 18411-18420.
186. Bamgbose, S.O.A.; Noamesi, B.K. Studies on cryptolepine .2. inhibition of carrageenan induced edema by cryptolepine. Planta Med., 1981, 41(4), 392-396.
187. Cimanga, K.; DeBruyne, T.; Lasure, A.; VanPoel, B.; Pieters, L.; Claeys, M.; VandenBerghe, D.; Kambu, K.; Tona, L.; Vlietinck, A.J. In vitro biological activities of alkaloids from cryptolepis sanguinolenta. Planta Med., 1996, 62(1), 22-27. (Pubitemid 26056304)
188. Wright, C.W.; Phillipson, J.D.; Awe, S.O.; Kirby, G.C.; Warhurst, D.C.; QuetinLeclercq, J.; Angenot, L. Antimalarial activity of cryptolepine and some other anhydronium bases. Phytother. Res., 1996, 10(4), 361-363. (Pubitemid 26195883)
189. Wright, C.W.; Addae-Kyereme, J.; Breen, A.G.; Brown, J.E.; Cox, M.F.; Croft, S.L.; Gokcek, Y.; Kendrick, H.; Phillips, R.M.; Pollet, P.L. Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. J. Med. Chem., 2001, 44(19), 3187-3194. (Pubitemid 32862349)
190. Kirby, G.C.; Paine, A.; Warhurst, D.C.; Noamese, B.K.; Phillipson, J.D. In-Vitro and in-Vivo Antimalarial Activity of Cryptolepine, a Plant-Derived Indoloquinoline. Phytother. Res., 1995, 9(5), 359-363.
191. Paulo, A.; Duarte, A.; Gomes, E.T. In-vitro antibacterial screening of cryptolepis-sanguinolenta alkaloids. J. Ethnopharmacol., 1994, 44(2), 127-130.
192. Paulo, A.; Pimentel, M.; Viegas, S.; Pires, I.; Duarte, A.; Cabrita, J.; Gomes, E.T. Cryptolepis sanguinolenta activity against diarrheal bacteria. J. Ethnopharmacol., 1994, 44(2), 73-77. (Pubitemid 24330224)
193. Oyekan, A.O.; Okafor, J.P.O. Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. J. Ethnopharmacol., 1989, 27(1-2), 141-148.
194. Oyekan, A.O.; Botting, J.H.; Noamesi, B.K. Cryptolepine inhibits platelet-aggregation in vitro and in vivo and stimulates fibrinolysis ex vivo. Gen. Pharmacol., 1988, 19(2), 233-237.
195. Oyekan, A.O.; Ablordeppey, S.Y. Effects of cryptolepine on collagen-induced aggregation and on the mobilization and metabolism of arachidonic-acid by rabbit platelets. Gen. Pharmacol., 1993, 24(5), 1285-1290.
196. Oyekan, A.O.; Ablordeppey, S.Y. The Mechanism(S) of the Anti-aggregatory Effects of Cryptolepine - the Role of Cyclic Adenosine- Monophosphate and Cellular Ca-2+. Gen. Pharmacol., 1993, 24(2), 461-469.
197. Olajide, O.A.; Heiss, E.H.; Schachner, D.; Wright, C.W.; Vollmar, A.M.; Dirsch, V.M. Synthetic cryptolepine inhibits DNA binding of NF-kappa B. Bioorg. Med. Chem., 2007, 15(1), 43-49.
198. Liang, M.C.; Bardhan, S.; Pace, E.A.; Rosman, D.; Beutler, J.A.; Porco, J.A.; Gilmore, T.D. Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity. Biochem. Pharmacol., 2006, 71(5), 634-645.
199. Li, C.M.; Pace, E.A.; Liang, M.C.; Lobkovsky, E.; Gilmore, T.D.; Porco, J.A. Total synthesis of the NF-kappa B inhibitor (-)- cycloepoxydon: Utilization of tartrate-mediated nucleophilic epoxidation. J. Am. Chem. Soc., 2001, 123(45), 11308-11309.
200. Hu, Y.B.; Li, C.M.; Kulkarni, B.A.; Strobel, G.; Lobkovsky, E.; Torczynski, R.M.; Porco, J.A. Exploring chemical diversity of epoxyquinoid natural products: Synthesis and biological activity of (-)-jesterone and related molecules. Org. Lett., 2001, 3(11), 1649-1652.
201. Kakeya, H.; Onose, R.; Koshino, H.; Yoshida, A.; Kobayashi, K.; Kageyama, S.; Osada, H. Epoxyquinol A, a highly functionalized pentaketide dimer with antiangiogenic activity isolated from fungal metabolites. J. Am. Chem. Soc., 2002, 124(14), 3496-3497.
202. Li, C.M.; Bardhan, S.; Pace, E.A.; Liang, M.C.; Gilmore, T.D.; Porco, J.A. Angiogenesis inhibitor epoxyquinol A: Total synthesis and inhibition of transcription factor NF-kappa B. Org. Lett., 2002, 4(19), 3267-3270.
203. Liang, M.C.; Bardhan, S.; Porco, J.A.; Gilmore, T.D. The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in I kappa B alpha-deficient diffuse large B-cell lymphoma cell line. Cancer Lett., 2006, 241(1), 69-78.
204. Fukazawa, H.; Uehara, Y.; Murakami, Y.; Mizuno, S.; Hamada, M.; Takeuchi, T. Labeling of V-Src and Bcr-Abl tyrosine kinases with [C-14] herbimycin-a and its use in the elucidation of the kinase inactivation mechanism. FEBS Lett., 1994, 340(3), 155-158. (Pubitemid 24080939)
205. Fukazawa, H.; Li, P.M.; Yamamoto, C.; Murakami, Y.; Mizuno, S.; Uehara, Y. Specific-inhibition of cytoplasmic protein tyrosine kinases by herbimycin-a in vitro. Biochem. Pharmacol., 1991, 42(9), 1661-1671.
206. Uehara, Y.; Fukazawa, H. Use and selectivity of herbimycin-a as inhibitor of protein-tyrosine kinases. Meth. Enzymol., 1991, 201, 370-379.
207. Iwasaki, T.; Uehara, Y.; Graves, L.; Rachie, N.; Bomsztyk, K. Herbimycin-a blocks Il-1-induced Nf-kappa-B DNA-binding activity in lymphoid-cell lines. FEBS Lett., 1992, 298(2-3), 240-244.
208. Mahon, T.M.; Oneill, L.A.J. Studies into the effect of the tyrosine kinase inhibitor herbimycin-a on Nf-kappa-B activation in T-lymphocytes - evidence for covalent modification of the P50 subunit. J. Biol. Chem., 1995, 270(48), 28557-28564.
209. Ogino, S.; Tsuruma, K.; Uehara, T.; Nomura, Y. Herbimycin A abrogates nuclear Factor-kappa B activation by interacting preferentially with the I kappa B kinase beta subunit. Mol. Pharmacol., 2004, 65(6), 1344-1351. (Pubitemid 38668293)
210. Coon, J.T.; Ernst, E. Andrographis paniculata in the treatment of upper respiratory tract infections: A systematic review of safety and efficacy. Planta Med., 2004, 70(4), 293-298. (Pubitemid 38594598)
211. Samy, R.P.; Thwin, M.M.; Gopalakrishnakone, P. Phytochemistry, pharmacology and clinical use of Andrographis paniculata. Nat. Prod. Commun., 2007, 2(5), 607-618.
212. Habtemariam, S. Andrographolide inhibits the tumour necrosis factor-alpha-induced upregulation of ICAM-1 expression and endothelial-monocyte adhesion. Phytother. Res., 1998, 12(1), 37-40. (Pubitemid 28076252)
213. Chiou, W.F.; Lin, J.J.; Chen, C.F. Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide. Br. J. Pharmacol., 1998, 125(2), 327-334.
214. Chiou, W.F.; Chen, C.F.; Lin, J.J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br. J. Pharmacol., 2000, 129(8), 1553-1560. (Pubitemid 30218995)
215. Wang, T.G.; Liu, B.; Zhang, W.; Wilson, B.; Hong, J.S. Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J. Pharmacol. Exp. Ther., 2004, 308(3), 975-983.
216. Xia, Y.F.; Ye, B.Q.; Li, Y.D.; Wang, J.G.; He, X.J.; Lin, X.F.; Yao, X.S.; Ma, D.W.; Slungaard, A.; Hebbel, R.P.; Key, N.S.; Geng, J.G. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J. Immunol., 2004, 173(6), 4207-4217.
217. Hidalgo, M.A.; Romero, A.; Figueroa, J.; Cortes, P.; Concha, II; Hancke, J.L.; Burgos, R.A. Andrographolide interferes with binding of nuclear factor-kappa B to DNA in HL-60-derived neutrophilic cells. Br. J. Pharmacol., 2005, 144(5), 680-686.